Structural elucidation of a PDE-5 inhibitor detected as an adulterant in a health supplement

被引：21

作者：

Ge, Xiaowei ^{[2
]}

Low, Min-Yong ^{[2
]}

Zou, Peng ^{[2
]}

Lin, Li ^{[1
]}

Yin, Sharon Oh Sze ^{[2
]}

Bloodworth, Bosco C. ^{[2
]}

Koh, Hwee-Ling ^{[1
]}

机构：

[1] Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 117543, Singapore

[2] Hlth Sci Author, Ctr Analyt Sci, Singapore 169078, Singapore

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2008年 / 48卷 / 04期

关键词：

Health supplement; PDE-5; inhibitor; Adulterant; Liquid chromatography (LC); Mass spectrometry (MS); Nuclear magnetic resonance (NMR);

D O I：

10.1016/j.jpba.2008.08.019

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

A PDE-5 inhibitor was detected and isolated from a health supplement claimed to be a preparation of fresh oyster extracts and be able to promote and support healthy sexual function and endurance, etc. The structure of this PDE-5 inhibitor was elucidated using LC-UV, LC-TOF-MS, MS-MS, IR spectroscopy, and 2D NMR. It was characterized as 8-(2-(4-(hydroxymethyl)piperidin-1-yl)benzylamino)-3-ethyl-1-Himidazo[4,5-g]quinazoline-2(3H)-thione, a compound reported to be a PDE-5 inhibitor. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：1070 / 1075

页数：6

共 50 条

[31] Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Schiefer, J
Sparing, R
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (04) : 383 - 384
[32] Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
J Schiefer
R Sparing
International Journal of Impotence Research, 2005, 17 : 383 - 384
[33] Association of PDE-5 inhibitor use in men with ED and sexual function of female partners
Fisher, W
Rosen, RC
Eardley, I
Niederberger, C
Sand, M
JOURNAL OF SEX RESEARCH, 2006, 43 (01) : 16 - 16
[34] TREATMENT PATTERNS AMONG PATIENTS PRESCRIBED PDE-5 INHIBITOR MONOTHERAPY FOR PULMONARY HYPERTENSION
Yeaw, J.
Lickert, C.
Drake, W.
De, A. P.
Wade, R. L.
VALUE IN HEALTH, 2016, 19 (03) : A59 - A59
[35] ROLE OF PDE-5 INHIBITOR IN THE TREATMENT OF CHRONIC PELVIC PAIN SYNDROME: A RANDOMIZED CONTROL TRIAL
Singh, Prabhjot
Shukla, Abhishek
Dogra, Prem Nath
JOURNAL OF UROLOGY, 2017, 197 (04): : E119 - E119
[36] Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects
Kim, Bo-Hyung
Lim, Hyeong-Seok
Chung, Jae-Yong
Kim, Jung-Ryul
Lim, Kyoung Soo
Sohn, Dong-Ryul
Cho, Joo-Youn
Yu, Kyung-Sang
Shin, Sang-Goo
Paick, Jae-Seung
Jang, In-Jin
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (06) : 848 - 854
[37] EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF UDENAFIL, A SELECTIVE PDE-5 INHIBITOR IN MALE SUBJECTS.
Kim, A.
Lee, J.
Lee, H.
Jeong, S.
Jung, Y.
Kim, H.
Lim, Y.
Rhee, S.
Yu, K.
Cho, J.
Shin, S.
Bahng, M.
Lim, K.
Jang, I.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S47 - S48
[38] Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
Poch, David S.
BMC PULMONARY MEDICINE, 2016, 16
[39] Solid state of a new PDE-5 inhibitor DA-8159: Characterization, dissolution, transformation
Ji Yoon Ryu
Young-Taek Sohn
Archives of Pharmacal Research, 2012, 35 : 861 - 866
[40] Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
David S. Poch
BMC Pulmonary Medicine, 16

← 1 2 3 4 5 →